Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

for the ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG)

Research output: Contribution to journalReview articlepeer-review

99 Scopus citations

Abstract

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).

Original languageEnglish
JournalTherapeutic Advances in Neurological Disorders
Volume14
DOIs
StatePublished - 2021
Externally publishedYes

Keywords

  • disease-modifying therapy
  • guideline
  • multiple sclerosis
  • treatment recommendation

Fingerprint

Dive into the research topics of 'Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)'. Together they form a unique fingerprint.

Cite this